Verrica Pharmaceuticals (NASDAQ:VRCA) CEO Jayson Rieger Purchases 5,000 Shares of Stock

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) CEO Jayson Rieger bought 5,000 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was bought at an average cost of $4.91 per share, with a total value of $24,550.00. Following the completion of the transaction, the chief executive officer owned 207,593 shares in the company, valued at approximately $1,019,281.63. This trade represents a 2.47% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Verrica Pharmaceuticals Stock Performance

Verrica Pharmaceuticals stock opened at $4.68 on Wednesday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.33 and a current ratio of 1.45. Verrica Pharmaceuticals Inc. has a fifty-two week low of $3.28 and a fifty-two week high of $9.82. The stock has a market cap of $80.40 million, a price-to-earnings ratio of -2.80 and a beta of 1.49. The stock’s 50 day simple moving average is $5.65 and its two-hundred day simple moving average is $5.92.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on VRCA. Wall Street Zen cut Verrica Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, July 15th. Zacks Research raised Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Finally, HC Wainwright started coverage on shares of Verrica Pharmaceuticals in a report on Tuesday, May 26th. They set a “buy” rating and a $12.00 target price for the company. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Verrica Pharmaceuticals has a consensus rating of “Hold” and an average target price of $14.50.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Several institutional investors have recently bought and sold shares of VRCA. Man Group plc bought a new stake in Verrica Pharmaceuticals in the fourth quarter worth $94,000. Quadrature Capital Ltd purchased a new position in shares of Verrica Pharmaceuticals during the fourth quarter valued at approximately $99,000. Bridgeway Capital Management LLC bought a new position in Verrica Pharmaceuticals in the 3rd quarter valued at $52,000. Beck Mack & Oliver LLC purchased a new position in Verrica Pharmaceuticals in the 4th quarter worth about $100,000. Finally, XTX Topco Ltd purchased a new position in shares of Verrica Pharmaceuticals during the fourth quarter worth approximately $122,000. 42.45% of the stock is owned by hedge funds and other institutional investors.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical?stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off?label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next?generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.